EVEREST MED (01952) saw its shares rise by nearly 5% during the morning trading session. At the time of writing, the stock was up 4.11%, trading at HK$37.96 with a turnover of HK$49.56 million.

On March 13, EVEREST MED announced positive top-line data from its Phase IIa study of the ophthalmic pipeline candidate VIS-101 for the treatment of wet age-related macular degeneration (wet AMD). Based on these encouraging clinical results, the company plans to initiate a Phase IIb clinical study for VIS-101 in the second half of 2026, followed by a global Phase III clinical study in 2027.

Notably, on March 9, EVEREST MED announced that the first prescription in mainland China for its core autoimmune disease product, VELSIPITY (arginine etermod tablets), was issued at the First Affiliated Hospital of Sun Yat-sen University. This marks the official entry of this innovative therapy into clinical use in China. VELSIPITY has also been prescribed simultaneously at eight top-tier hospitals across seven key cities—Guangzhou, Shanghai, Hangzhou, Xi'an, Chongqing, Beijing, and Nanjing—ensuring patient coverage in major regions nationwide on the first day of its launch.